[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://lyell.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 224, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 71, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 80000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 962226, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles W. Newton", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 744737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 775967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Lee Ph.D.", "age": 46, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Lang J.D.", "age": 47, "title": "Chief Business Officer, Chief Legal Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 596253, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 62, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Rose", "title": "Senior Vice President of Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.22, "open": 1.26, "dayLow": 1.16, "dayHigh": 1.27, "regularMarketPreviousClose": 1.22, "regularMarketOpen": 1.26, "regularMarketDayLow": 1.16, "regularMarketDayHigh": 1.27, "beta": -0.483, "forwardPE": -1.452381, "volume": 573629, "regularMarketVolume": 573629, "averageVolume": 1084820, "averageVolume10days": 1917850, "averageDailyVolume10Day": 1917850, "bid": 1.2, "ask": 1.24, "bidSize": 600, "askSize": 600, "marketCap": 340649632, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 3.256, "priceToSalesTrailing12Months": 5407.137, "fiftyDayAverage": 1.22738, "twoHundredDayAverage": 1.863045, "currency": "USD", "enterpriseValue": -41322852, "floatShares": 181814503, "sharesOutstanding": 279220992, "sharesShort": 10759090, "sharesShortPriorMonth": 13222068, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.042, "heldPercentInsiders": 0.14061, "heldPercentInstitutions": 0.62114, "shortRatio": 13.91, "shortPercentOfFloat": 0.0596, "bookValue": 2.068, "priceToBook": 0.589942, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -203988992, "trailingEps": -0.79, "forwardEps": -0.84, "pegRatio": 0.19, "enterpriseToRevenue": -655.918, "enterpriseToEbitda": 0.21, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LYEL", "underlyingSymbol": "LYEL", "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "firstTradeDateEpochUtc": 1623936600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "c5ad7970-8aa2-3c85-a7aa-1e907d8cc7ab", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.22, "targetHighPrice": 4.0, "targetLowPrice": 1.0, "targetMeanPrice": 2.0, "targetMedianPrice": 1.0, "recommendationMean": 3.2, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 440547008, "totalCashPerShare": 1.578, "ebitda": -196600000, "totalDebt": 58575000, "quickRatio": 13.146, "currentRatio": 13.429, "totalRevenue": 63000, "debtToEquity": 11.037, "returnOnAssets": -0.19115, "returnOnEquity": -0.33216, "freeCashflow": -83122752, "operatingCashflow": -155787008, "revenueGrowth": 0.36, "grossMargins": 1.0, "operatingMargins": -1485.4413, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-11"}]